Clinical trials: Hematologic Disorders
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
This phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439279
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.
- Trial name
- NCT01275196
- Testing
- Nilotinib, Imatinib
- Where
- 12 sites in China
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
This phase II trial studies how well bortezomib works in treating patients with high-risk acute myeloid leukemia (AML) in remission.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01465386
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fred Hutchinson Cancer Center
Sickle Cell Disease, Thalassemia
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Primary Objective 1. Define the pharmacokinetics of liquid-formulated HU in infants (9 months to <2 years) 2. Assess the relative bioavailability of HU "sprinkles" compared to capsules in children and adolescents (≥2 to 18…
- Trial name
- NCT03825341
- Testing
- Hydroxyurea, Hydroxyurea Oral Capsule
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- St. Jude Children's Research Hospital
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
- Trial name
- NCT02879305
- Testing
- Daprodustat, rhEPO, Iron therapy
- Where
- 462 sites in United States, Argentina and 33 more
- Volunteers
- 2,964 people
- Sponsor
- GlaxoSmithKline
Leukemia, Myeloid, Acute
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
The trial will be performed in two parts, a phase I part and a phase IIa part. In the phase I part of the trial, BI 6727 will be investigated as monotherapy and in combination with low dose cytarabine (LD-Ara-C) in patients with…
- Trial name
- NCT00804856
- Testing
- Volasertib, Cytarabine
- Where
- 27 sites in Austria, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease, Iron-deficiency Anemia
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
The long-term goal is to assess the fall in kidney function measured by glomerular filtration rate (GFR) when patients with chronic kidney disease (CKD) are exposed to intravenous iron (IVIR).
- Trial name
- NCT00830037
- Testing
- IV Iron, Ferrous Sulfate
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Indiana University
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well lenalidomide and obinutuzumab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back (recurrent) or does not respond to treatment…
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Trial name
- NCT02225275
- Testing
- Lenalidomide, Obinutuzumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of the study is to determine whether the combination of LDE225 (sonidegib) plus bortezomib is safe and effective in the treatment of relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT02254551
- Testing
- LDE225, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- SCRI Development Innovations, LLC
CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia)
Stem Cell Transplantation for Patients With Cancers of the Blood
This study will try to improve the safety and effectiveness of stem cell transplant procedures in patients with cancers of the blood.
- Conditions
- CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia
- Trial name
- NCT00467961
- Testing
- Miltenyi system
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome
- Trial name
- NCT02065869
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
This phase II clinical trial is studying how well giving busulfan, fludarabine phosphate, and anti-thymocyte globulin followed by donor stem cell transplant and azacitidine works in treating patients with high-risk…
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia
- Trial name
- NCT01168219
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine
- Where
- 17 sites in United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Aplastic, Red-Cell Aplasia, Pure
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
This study will test whether the immune-suppressing drug rituximab can increase blood counts and reduce the need for transfusions in patients with moderate aplastic anemia, pure red cell aplasia, or Diamond Blackfan anemia.
- Conditions
- Anemia, Aplastic, Red-Cell Aplasia, Pure, Anemia, Diamond-Blackfan
- Trial name
- NCT00229619
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myeloma
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.
- Trial name
- NCT01432600
- Testing
- Pomalidomide, Dexamethasone, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
RATIONALE: Vorinostat may stop the growth of cancer cells by interfering with various proteins needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin (GO), can block cancer growth in different ways.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00673153
- Testing
- gemtuzumab ozogamicin, vorinostat, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders
Imatinib Mesylate in Treating Patients With Myelofibrosis
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in…
- Trial name
- NCT00245128
- Testing
- imatinib mesylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant.
- Conditions
- Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin
- Trial name
- NCT01660607
- Testing
- CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Stanford University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00540995
- Testing
- busulfan, etoposide, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.